Biocom’s Terri Somers is out with the latest Deals and Data.

This issue highlights our story on the issue of biosimilars and the battle going on in Washington D.C.

It also links to news on new National Institutes of Health guidelines on stem cells, and Xconomy’s chat with a couple of angel investors.


Leave a comment

We expect all commenters to be constructive and civil. We reserve the right to delete comments without explanation. You are welcome to flag comments to us. You are welcome to submit an opinion piece for our editors to review.

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.